Your account is not claimed yet. You can sign up with ORCID to claim your account.

Peter W M Johnson (Peter Johnson, Peter W Johnson)

ResearcherID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 19

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Blood advances

Blood

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

John R Davies, Laura K Hilton, Aixiang Jiang, Sharon L Barrans, Catherine Burton, Peter W M Johnson, Andrew John Davies, Ming-Qing Du, Reuben M Tooze, Francesco Cucco, Matthew A Care, Ryan D Morin, Christian Steidl, Chulin Sha, David Robert Westhead, David W Scott
Comparison of MHG and DZsig reveals shared biology and a core overlap group with inferior prognosis in DLBCL. Blood advances (2023)
Stefano Luminari, Alexander Fossa, Judith Trotman, Daniel Molin, Francesco d'Amore, Gunilla Enblad, Leanne Berkahn, Sally F Barrington, John Radford, Massimo Federico, Amy A Kirkwood, Peter W M Johnson
Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Peter W M Johnson
Are we reaching the maximum cure rate for Hodgkin lymphoma? Hematological oncology (2023)
Jack G Fisher, Amber D P Doyle, Lara V Graham, Shreyanshi Sonar, Benjamin Sale, Isla Henderson, Luis Del Rio, Peter W M Johnson, Yosef Landesman, Mark S Cragg, Francesco Forconi, Christopher J Walker, Salim I Khakoo, Matthew D Blunt
XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression. Leukemia (2023)
Andrew John Davies, Sharon Barrans, Louise Stanton, Josh Caddy, Sam Wilding, Geoff Saunders, Christoph Mamot, Urban Novak, Andrew McMillan, Paul Fields, Graham P Collins, Richard Stephens, Francesco Cucco, Chulin Sha, Moniek van Hoppe, Reuben M Tooze, John R Davies, Gareth O Griffiths, Anna Schuh, Catherine Burton, David Robert Westhead, Ming-Qing Du, Peter W M Johnson
Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Peter W M Johnson, Sriram Balasubramanian, Brendan Hodkinson, S Martin Shreeve, Steven Sun, Srimathi Srinivasan, Andrew J Steele, Jessica Vermeulen, Laurie H Sehn, Wyndham H Wilson
Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL co-expressing BCL2 and MYC in the phase 3 PHOENIX trial. Blood advances (2023)
Angie Mae Rodday, Susan K Parsons, Jenica N Upshaw, Jonathan W Friedberg, Andrea Gallamini, Eliza A Hawkes, David C Hodgson, Peter W M Johnson, Brian K Link, Eric Mou, Kerry J Savage, Pier Luigi Luigi Zinzani, Matthew J Maurer, Andrew M Evens
The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Paul Skipp, Alistair Bailey, Katy J McCann, Oliver Wood, Robert C Walker, Robert Parker, Nicola Ternette, Tim Elliott, Timothy J Underwood, Peter W M Johnson, Paul J Skipp
Identification of neoantigens in oesophageal adenocarcinoma. Immunology (2022)
Peter W M Johnson
Smart salvage treatment for Hodgkin lymphoma. Blood 139 (25) (2022)
Findlay Bewicke-Copley, Koorosh Korfi, Shamza Araf, Brendan Hodkinson, Emil Kumar, Thomas Cummin, Margaret Ashton-Key, Sharon L Barrans, Suzan Jl van Hoppe, Cathy Burton, Mohamed Elshiekh, Simon A Rule, Nicola Crosbie, Andrew James Clear, Maria Calaminici, Hendrik Friedrich Peter Runge, Robert K Hills, David W Scott, Lisa M Rimsza, Geetha Menon, Chulin Sha, John Davies, Ai Nagano, Andrew John Davies, Daniel Painter, Alexandra G Smith, John G Gribben, Kikkeri N Naresh, David Robert Westhead, Jessica Okosun, Andrew J Steele, Daniel James Hodson, Sriram Balasubramanian, Peter W M Johnson, Jun Wang, Jude Fitzgibbon
Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type Diffuse Large B Cell Lymphoma. Blood advances (2022)
Matthew D Blunt, Sócrates Herrera Valencia, Jack G Fisher, Lara V Graham, Amber D P Doyle, Rebecca Fulton, Matthew J Carter, Marta E Polak, Peter W M Johnson, Mark S Cragg, Francesco Forconi, Salim I Khakoo
KIR2DS2 Expression Identifies NK Cells With Enhanced Anticancer Activity. Journal of immunology (Baltimore, Md. : 1950) 209 (2) (2022)
Richard D Neal, Peter W M Johnson, Christina A Clarke, Stephanie A Hamilton, Nan Zhang, Harpal Kumar, Charles Swanton, Peter D Sasieni
Cell-Free DNA-Based Multi-Cancer Early Detection Test in an Asymptomatic Screening Population (NHS-Galleri): Design of a Pragmatic, Prospective Randomised Controlled Trial. Cancers 14 (19) (2022)
Angie Mae Rodday, Susan K Parsons, Jenica N Upshaw, Jonathan W Friedberg, Andrea Gallamini, Eliza A Hawkes, David C Hodgson, Peter W M Johnson, Brian K Link, Eric Mou, Kerry J Savage, Pier Luigi Luigi Zinzani, Matthew J Maurer, Andrew M Evens
The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Jemma Longley, Peter W M Johnson
Personalized medicine for Hodgkin lymphoma: Mitigating toxicity while preserving cure. Hematological oncology (2021)
James Heward, Lola Konali, Annalisa D'Avola, Karina Close, Alison Yeomans, Martin Philpott, James E Dunford, Tahrima Rahim, Ahad F Al Seraihi, Jun Wang, Koorosh Korfi, Shamzah Araf, Sameena Iqbal, Findlay Bewicke-Copley, Emil Kumar, Darko Barisic, Maria Calaminici, Andrew James Clear, John G Gribben, Peter W M Johnson, Richard Neve, Pedro Rodriguez Cutillas, Jessica Okosun, Udo Oppermann, Ari M Melnick, Graham Packham, Jude Fitzgibbon
KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas. Blood 138 (5) (2021)
Allan Relecom, Massimo Federico, Joseph M Connors, Bertrand Coiffier, Irene Biasoli, Alden Alberto Moccia, Gilles Salles, Thomas McKee, Raymond Miralbell, Peter Borchmann, John Kuruvilla, Peter W M Johnson, Franco Cavalli, Martine Delavy, Pierre-Yves Dietrich, Antoine Flahault
Resources-Stratified Guidelines for Classical Hodgkin Lymphoma. International journal of environmental research and public health 17 (5) (2020)
Timothy A Yap, Jane N Winter, Lisa Giulino-Roth, Jemma Longley, Juanita Lopez, Jean Marie Michot, John P Leonard, Vincent Ribrag, Michael T McCabe, Caretha L Creasy, Melissa Stern, Teodora Pene Dumitrescu, Xiaowei Wang, Steve Frey, Jennifer Carver, Thierry Horner, Choon Oh, Ahmed Khaled, Arindam Dhar, Peter W M Johnson
Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 25 (24) (2019)
Samantha Drennan, Giorgia Chiodin, Annalisa D'Avola, Ian Tracy, Peter W M Johnson, Livio Trentin, Andrew J Steele, Graham Packham, Freda K Stevenson, Francesco Forconi
Ibrutinib Therapy Releases Leukemic Surface IgM from Antigen Drive in Chronic Lymphocytic Leukemia Patients. Clinical cancer research : an official journal of the American Association for Cancer Research 25 (8) (2018)
Sean H Lim, Peter W M Johnson
Optimizing therapy in advanced-stage Hodgkin lymphoma. Blood 131 (15) (2018)

Peter W M Johnson.css-eqlu8i{font-size:small;padding-left:4px;} (Peter Johnson, Peter W Johnson)

Publication Activity (10 Years)

Top Topics

Top Venues

Peter W M Johnson (Peter Johnson, Peter W Johnson)